Lorazepam in a Neuroleptic Malignant Syndrome Case: Improvement Followed a Treatment Bundle

A case involving renal failure, lithium toxicity, and changing psychotropics cannot isolate lorazepam’s contribution to recovery.

Several phases of illness

A patient with longstanding bipolar disorder developed infection and lithium-associated renal failure, followed by further medication changes and neuroleptic malignant syndrome. Lorazepam, amantadine, and bromocriptine were introduced during management, and the condition improved.

Complex exposure history limits attribution

The report supports careful consideration of interacting illness and drugs, but does not prove the independent effect of any one rescue medicine. Withdrawal of suspected agents and supportive care are also part of the course. The patient’s fever and altered state cannot be assigned to a benzodiazepine merely because it appears in the medication record after deterioration. A retrospective assessment should distinguish treatments before onset from those given in response. One case cannot establish a comparative regimen or quantify the risk of a particular combination.

Source paper

Original analysis of the supplied journal article, identified as PMC7168987.

Related research

• Down-Syndrome Catatonia Series Found Improvement With Combined Care but Ongoing Treatment Needs
• Lorazepam Improvement in Wilson’s Disease Catatonia Did Not Replace the Copper-Metabolism Diagnosis